283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)
oleh: Alexander Stevenson, Jianjun Gao, Pavlos Msaouel, Nizar Tannir, Mehmet Altan, Shi-Ming Tu, Michael Chisamore, Matthew Campbell, George Blumenschein, Xiuning Le, Frank Mott, Amishi Shah, Jordi Rodon, Imke Mulder
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.